A phase III clinical trial to evaluate patient's preference of subcutaneous trastuzumab (SC) versus intravenous (IV) administration in patients with HER2 positive Advanced Breast Cancer (ABC) who have received intravenous trastuzumab at least 4 months and without disease progression
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ChangHER-SC
- 30 Mar 2017 Planned End Date changed from 1 May 2016 to 1 Jul 2018.
- 30 Mar 2017 Planned primary completion date changed from 1 Jun 2015 to 1 Jul 2018.
- 30 Mar 2017 Status changed to active, no longer recruiting.